

Basil S Lewis

List of Publications by Citations

Source: <https://exaly.com/author-pdf/289204/basil-s-lewis-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45
papers

11,294
citations

23
h-index

50
g-index

50
ext. papers

13,957
ext. citations

14.7
avg, IF

5
L-index

#	Paper	IF	Citations
45	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 981-92	59.2	5856
44	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
43	Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. <i>Circulation</i> , 2014 , 130, 1579-88	16.7	479
42	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2021-31	59.2	440
41	Dronedarone in high-risk permanent atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 2268-76	59.2	438
40	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 219-229	40	414
39	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2009-20	59.2	382
38	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). <i>Circulation</i> , 2018 , 137, 338-350	16.7	348
37	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 811-820	18.1	330
36	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019 , 21, 1169-1186	12.3	325
35	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2032-43	59.2	199
34	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. <i>European Heart Journal</i> , 2015 , 36, 281-7a	9.5	196
33	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , 2020 , 396, 1895-1904	40	162
32	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal</i> , 2016 , 37, 1015-23	9.5	68
31	Pantoprazole to Prevent Gastrointestinal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019 , 157, 403-412.e5	13.3	62
30	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. <i>Circulation</i> , 2020 , 141, 1841-1854	16.7	53
29	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	46

28	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 86-94	6.4	44
27	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017 , 38, 1710-1716	9.5	38
26	Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. <i>Neurology</i> , 2019 , 92, e1435-e1446	6.5	34
25	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	25
24	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. <i>JAMA Cardiology</i> , 2020 , 5, 709-713	16.2	25
23	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021 ,	9.5	17
22	Coronary Computed Tomography (CT) Angiography as a Predictor of Cardiac and Noncardiac Vascular Events in Asymptomatic Type 2 Diabetics: A 7-Year Population-Based Cohort Study. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	16
21	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. <i>American Heart Journal</i> , 2019 , 208, 81-90	4.9	16
20	Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. <i>European Heart Journal</i> , 2021 , 42, 4013-4021	9.5	16
19	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 42, 101-110	6.4	15
18	Perceived benefit after participating in positive or negative/neutral heart failure trials: the patients' perspective. <i>European Journal of Heart Failure</i> , 2001 , 3, 217-23	12.3	13
17	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal</i> , 2018 , 39, 2274-2281	9.5	12
16	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2014 , 168, 68-75.e2	4.9	12
15	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 ^{PP})-TIMI 50. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	12
14	Low cardiorespiratory fitness and coronary artery calcification: Complementary cardiovascular risk predictors in asymptomatic type 2 diabetics. <i>Atherosclerosis</i> , 2015 , 241, 634-40	3.1	10
13	Prognostic impact of abdominal fat distribution and cardiorespiratory fitness in asymptomatic type 2 diabetics. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 1146-53	3.9	8
12	Automatic assessment of coronary artery calcium score from contrast-enhanced 256-row coronary computed tomography angiography. <i>American Journal of Cardiology</i> , 2014 , 113, 7-11	3	6
11	Potentially Inappropriate Prescriptions in Heart Failure with Reduced Ejection Fraction (PIP-HFrEF). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	6

10	The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	5
9	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 97-103	6.4	4
8	Computer-assisted diagnosis of obstructive coronary atherosclerosis in patients undergoing 256-slice coronary computed tomography angiography: a comparison with invasive coronary angiography. <i>International Journal of Cardiology</i> , 2014 , 172, e130-1	3.2	3
7	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , 2021 , 42, 2995-3007	9.5	3
6	Automated Computer-Assisted Diagnosis of Obstructive Coronary Artery Disease in Emergency Department Patients Undergoing 256-Slice Coronary Computed Tomography Angiography for Acute Chest Pain. <i>American Journal of Cardiology</i> , 2015 , 116, 1017-21	3	2
5	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	2
4	The 894G Allele of the Endothelial Nitric Oxide Synthase 3 (eNOS) is Associated with Atrial Fibrillation in Chronic Systolic Heart Failure. <i>Journal of Atrial Fibrillation</i> , 2012 , 5, 757	0.8	1
3	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. <i>Stroke</i> , 2021 , 52, 2494-2501	6.7	1
2	MSc in clinical trials: a new flagship Working Group project. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 284	6.4	0
1	Atrial fibrillation and stroke prevention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f1-f2	6.4	